Healthy volunteers help uncover drug interaction risks
NCT ID NCT06028464
First seen Nov 05, 2025 · Last updated May 29, 2026 · Updated 22 times
Summary
This study looked at how taking multiple doses of carbamazepine, a common seizure medicine, changes the amount of the cancer drug zongertinib in the blood. Sixteen healthy men received zongertinib once, then later took it again after several days of carbamazepine. The goal was to see if carbamazepine speeds up the breakdown of zongertinib, which could affect how well the cancer drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
Conditions
Explore the condition pages connected to this study.